S5326

SB-271046A

≥98% (HPLC)

• Synonim(y): 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzo-thiophenesulfonamide hydrochloride
• Wzór empiryczny (zapis Hilla): C₂₀H₂₂ClN₃O₃S₂ · HCl
• Numer CAS: 209481-24-3
• Masa cząsteczkowa: 488.45
• NACRES: NA.77
• PubChem Substance ID: 329824453
• UNSPSC Code: 12352200
• MDL number: MFCD10565914
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100

Właściwości

• InChI: 1S/C20H22ClN3O3S2.ClH/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24;/h3-6,11-12,22-23H,7-10H2,1-2H3;1H
• SMILES string: Cl.COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N4CCNCC4
• InChI key: RMXZRJYGJMSDQK-UHFFFAOYSA-N
• assay: ≥98% (HPLC)
• form: powder
• solubility: DMSO: >20 mg/mL
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• Quality Level: 100

Opis

Biochem/physiol Actions

SB-271046A is a 5-HT6 receptor antagonist.

The first potent and selective 5-HT₆ antagonist. Training in cognitive tasks, as well as administration SB-271046, induces an increase in pERK1/2 and pCREB1 levels, while CREB2 levels are significantly reduced; cognition-enhancing properties of SB-271046 are attributed to the effect on pERK1/2, not pCREB1/2. SB-271046 reverses MK-801-induced, but not scopolamine-induced, learning impairments. However, with coadministration of galanthamine, both types of learning impairments were ameliorated.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: nwg
• flash_point_f: Not applicable
• flash_point_c: Not applicable